PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35142429-0	2022	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression.	Sorafenib	8-17	Nanog homeobox	Homo sapiens	98-103	
35142429-3	2022	The associations between NANOG and POU5F1 expressions with the sorafenib anticancer effects in primary cultured hepatocellular carcinoma (HCC) cells were investigated.	Sorafenib	63-72	Nanog homeobox	Homo sapiens	25-30	
35142429-5	2022	Sorafenib showed obvious downregulation of RAF/MEK/ERK signaling pathways and dose-dependent anti-proliferative effects only on s003 parent cell line, which showed the lowest expression of NANOG among all tested cell lines except one downregulated NANOG with upregulated POU5F1 s020 subgroup.	Sorafenib	0-9	Nanog homeobox	Homo sapiens	189-194	
35142429-5	2022	Sorafenib showed obvious downregulation of RAF/MEK/ERK signaling pathways and dose-dependent anti-proliferative effects only on s003 parent cell line, which showed the lowest expression of NANOG among all tested cell lines except one downregulated NANOG with upregulated POU5F1 s020 subgroup.	Sorafenib	0-9	Nanog homeobox	Homo sapiens	248-253	
35142429-7	2022	For the only one downregulated NANOG alone s015 subgroup, sorafenib which had no influence on its parent cell line inhibited proliferation in this subgroup.	Sorafenib	58-67	Nanog homeobox	Homo sapiens	31-36	
35142429-9	2022	On the contrary, sorafenib promoted proliferation in three (s003, s015, s071) out of four upregulated NANOG alone subgroups.	Sorafenib	17-26	Nanog homeobox	Homo sapiens	102-107	
35142429-11	2022	In conclusion, NANOG rather than POU5F1 expression is a critical marker for the anticancer effects of sorafenib on HCC.	Sorafenib	102-111	Nanog homeobox	Homo sapiens	15-20	
35142429-12	2022	The sorafenib anticancer effects on HCC cells with high NANOG expression were limited.	Sorafenib	4-13	Nanog homeobox	Homo sapiens	56-61	
35142429-13	2022	Sorafenib should be combined with other drug able to target cancer cells with high NANOG expression.	Sorafenib	0-9	Nanog homeobox	Homo sapiens	83-88	
30657254-0	2019	TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.	Sorafenib	51-60	Nanog homeobox	Homo sapiens	35-40	
30657254-10	2019	The TARBP2 protein was destabilized through autophagic-lysosomal proteolysis, thereby stabilizing the expression of the CSC marker protein Nanog, which facilitates sorafenib resistance in HCC cells.	Sorafenib	164-173	Nanog homeobox	Homo sapiens	139-144	
30405889-6	2018	The Notch1-Snail1 signaling pathway contributed to sorafenib resistance via increasing epithelial-mesenchymal transition (EMT) and EMT-mediated cancer stem cell (CSC) features, such as increased expression of Snail1, N-cadherin, ABCG2, and the stem cell related genes Nanog and Oct4, and decreased expression of E-cadherin.	Sorafenib	51-60	Nanog homeobox	Homo sapiens	268-273	
22473773-7	2012	In addition, we found that Nanog(Pos) CSCs exhibited resistance to therapeutic agents (e.g., sorafenib and cisplatin) and have a high capacity for tumor invasion and metastasis.	Sorafenib	93-102	Nanog homeobox	Homo sapiens	27-32